Enveric Biosciences, Inc. — Form 8-K
Filed November 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Enveric Biosciences reported Q3 2026 net loss of $2.5M ($0.57 per share) versus $3.4M in Q3 2025, with cash-on-hand of $5.6M as of September 30, 2026. The company completed IND-enabling ADMET studies for lead candidate EB-003 (non-hallucinogenic mescaline derivative) showing favorable absorption and reduced drug-drug interactions; preclinical qEEG study demonstrated brain penetration with activity pattern distinct from DMT; and secured U.S. patent allowance for EVM401 Series. IND submission planned with first-in-human Phase 1 trial to follow.
Why this rating
EB-003 advancement materially de-risks lead program; $2.5M quarterly burn against $5.6M cash gives ~9 months runway—critical near-term milestone dependency. Positive preclinical data supports regulatory path but not yet clinical proof.
Tradability signal
NO TRADE
No trade: positive news with only -0.3% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.04% over 4 hrs, n=508). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $1.51 ▲ 0.33% | at our read · unknown $1.51 | +10 min · unknown $1.54 ▲ 1.99% | +30 min · unknown $1.51 ▲ 0.00% | +1 hr · unknown $1.51 ▲ 0.00% | +4 hrs · unknown $1.46 ▼ 3.31% |
The stock had already moved -0.33% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.